Uluru (OTCMKTS:ULUR) and BIOFRONTERA AG/ADR (NASDAQ:BFRA) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their earnings, dividends, risk, profitability, institutional ownership, valuation and analyst recommendations.
This is a breakdown of recent ratings and target prices for Uluru and BIOFRONTERA AG/ADR, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Institutional & Insider Ownership
0.0% of BIOFRONTERA AG/ADR shares are owned by institutional investors. 1.1% of Uluru shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Risk & Volatility
Uluru has a beta of 1.75, indicating that its share price is 75% more volatile than the S&P 500. Comparatively, BIOFRONTERA AG/ADR has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500.
This table compares Uluru and BIOFRONTERA AG/ADR’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Earnings & Valuation
This table compares Uluru and BIOFRONTERA AG/ADR’s revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|BIOFRONTERA AG/ADR||$24.93 million||10.48||-$10.48 million||N/A||N/A|
Uluru has higher earnings, but lower revenue than BIOFRONTERA AG/ADR.
BIOFRONTERA AG/ADR beats Uluru on 7 of the 11 factors compared between the two stocks.
ULURU Inc., a specialty medical technology company, researches, develops, and commercializes a range of wound care and muco-adhesive film products based on its patented Nanoflex and OraDisc technologies in the United States and internationally. The company provides Altrazeal, a transforming powder dressing that is used for the treatment of various wounds, such as partial thickness burns, donor sites, and surgical and traumatic wounds, as well as chronic wounds, including diabetic foot, venous leg, and pressure ulcers. Its products also include Aphthasol paste for the treatment of canker sores; OraDisc A for canker sores; and OraDisc B, which is used for the treatment and management of oral pain. ULURU Inc. and is headquartered in Addison, Texas.
About BIOFRONTERA AG/ADR
Biofrontera AG, a biopharmaceutical company, engages in the development and commercialization pharmaceutical products for the treatment of dermatological conditions and diseases caused primarily by exposure to sunlight that result in sun damage to the skin. Its principal product is Ameluz, a prescription drug for the treatment of actinic keratosis. The company also offers BF-RhodoLED lamp, a photodynamic therapy for lesion-directed and field-directed treatment of actinic keratosis; and Belixos over-the-counter line of skin care cosmetics products. In addition, it is developing Ameluz for the treatment of basal cell carcinoma; BF-derm1 for the treatment of chronic and antihistamine-resistant urticaria; and BF-1 for the prophylactic treatment of migraine. The company offers its products primarily in the United States and Europe. Biofrontera AG has a collaboration and partnership agreement with Maruho Co., Ltd. The company was founded in 1997 and is headquartered in Leverkusen, Germany.
Receive News & Ratings for Uluru Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Uluru and related companies with MarketBeat.com's FREE daily email newsletter.